Lidolog Kit
FDA Recall NDC 76420-760

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Lidolog Kit (NDC 76420-760). A significant event, classified as Class III, was initiated on May 18, 2026 by Asclemed Usa, Inc.. The reported reason for this action was: "Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

May 2026 Class III Recall: Labeling

Recall Number
Class III Ongoing
Reason for Recall
Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan
Initiated
May 18, 2026
Reported
Jun 10, 2026
Quantity
168,300 vials

Recall Profile & Regulatory Data

Event ID
99024
Classification
Class III
Enforcement Status
Ongoing
Recalling Firm
Eugia US LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
US Nationwide.
Product Description
Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520. NDC: 55150-164-02
Batch or Lot Expiration Information
Lot# Lot, expiry: Lot 3LC26029A, exp Feb-2029; Lot 3LC26031A, exp Mar-2029
Affected Packages Involved in this Recall
76420-760-01Product
55150-164-02Product
70121-1049-5Product
67777-419-02Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.